| Revenue growth | Q2 +127% YoY; H1 +28% YoY |
|---|---|
| Margins | EBITDA 33.5% to 31.6% QoQ; PAT 26.7% to 27.3% |
| Demand visibility | ~70% sales backed by contracted volumes (FY21-23 data) |
Growth
Q2 revenue +127.1% YoY, +28.2% QoQ; PAT +96.6% YoY. Pharma intermediates & API +322% YoY; contrast media +80%; sweeteners -19%.
Outlook
No numeric guidance or capex disclosed. Peptide-fragment amino acid derivatives to ship Q4 FY27; Hyderabad R&D operational, 40 staff.
Risks
Gross margin fell to 48.5% from 53.2% QoQ; EBITDA margin down to 31.6%. Sweeteners declining; other income boosted by FX gains.
Last quarter's promises, checked
Delivered
- Hyderabad R&D 'operational this month' (Aug-26) → operational, 40 staff (= BEAT)
- PI/API visibility '3-4 qtrs' → PI/API +322% YoY (= BEAT)
Partly delivered
- 3 CM launches in FY27 → 1 CM intermediate validated, launches not disclosed (= PARTIAL)
- FY27 capex INR250cr vs INR400cr 'similar' → not disclosed (= PARTIAL)
Investor Presentation filed with BSE, NSE: BLUEJET. Summary written with AI assistance from the document.
Blue Jet Healthcare Ltd: key numbers
- Share price
- ₹553.80
- Market cap
- ₹9,607 Cr
- Revenue (annual)
- ₹947.3 Cr
- Net profit (annual)
- ₹247.8 Cr
- P/E (TTM)
- 33.7×Sector 43.0×
- Promoter holding
- 73.15%-6.66% QoQ
- FII holding
- 0.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Blue Jet Healthcare Ltd
All →Blue Jet Healthcare Earnings Call Transcript: Key Takeaways
Record Q2 FY27 revenue of about ₹376 Cr (+28% QoQ), but gross margin fell 4ppt to 49% on West Asia raw-material costs. Management gave no numerical forward guidance; margin recovery depends on price hikes from Q3.
Blue Jet Healthcare Other Announcement
Blue Jet Healthcare filed CARE Ratings' monitoring agency report for the QIP proceeds for the quarter ended 30 September 2026. The report shows nil deviation from the offer objects on the ₹800 crore issue.
Blue Jet Healthcare Q2 FY27 Results: Net Profit ₹102.5 Cr, Up 96.7% YoY
Blue Jet Healthcare reported standalone financial results for the quarter ended September 30, 2026. Revenue from operations reached Rs.375.74 Crore with a net profit of Rs.102.52 Crore.
- Key figure
- Net profit ₹102.5 Cr · +96.7% YoY
Blue Jet Healthcare Board Meeting Date
Blue Jet Healthcare scheduled a board meeting on November 5, 2026, to consider Q1 FY27 unaudited results. No financial figures are disclosed.
Blue Jet Healthcare Other Announcement
Blue Jet Healthcare Limited filed its quarterly shareholding pattern for the period ended 30 September 2026 under Regulation 31(1)(b). Promoter and promoter group hold about 73.15% of the equity.
Blue Jet Healthcare Other Announcement
Blue Jet Healthcare Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by regulatory norms.